Incretin effect: difference between revisions
Diff·revision 54 → 55·21:04, 16 Sep 2025
Difference between revision 54 and revision 55 of Incretin effect. 2 lines changed; the page grew by 224 bytes.
| Revision 54 — 08:26, 3 Sep 2025 CostPerMgCory (talk) rv restoration of unsourced claim 7,134 bytes ±0 | Revision 55 — 21:04, 16 Sep 2025 IncretinIvo (talk) update infobox 7,358 bytes +224 | ||
|---|---|---|---|
| 38 | The defect is asymmetric: GIP-mediated insulin secretion is lost disproportionately, whereas GLP-1 responsiveness is better preserved, though also impaired. This asymmetry is clinically important: it explains why GLP-1-directed drugs work as monotherapy in type 2 diabetes whereas GIP-directed drugs do not, and why the later addition of GIP agonism to GLP-1 monotherapy produces further benefit.{{r|nauck2018}} | 38 | The defect is asymmetric: GIP-mediated insulin secretion is lost disproportionately, whereas GLP-1 responsiveness is better preserved, though also impaired. This asymmetry is clinically important: it explains why GLP-1-directed drugs work as monotherapy in type 2 diabetes whereas GIP-directed drugs do not, and why the later addition of GIP agonism to GLP-1 monotherapy produces further benefit.{{r|nauck2018}} |
| 39 | 39 | ||
| + | 40 | In type 1 diabetes, the incretin effect is preserved in those with residual beta-cell function, suggesting the lesion in T2D is beta-cell-intrinsic rather than a defect in hormone secretion or action at the receptor level. | |
| + | 41 | ||
| 40 | == References == | 42 | == References == |
| 41 | {{reflist}} | 43 | {{reflist}} |